IRDAI barred four insurers from opening any new place of business for six months after finding they breached Expenses of Management limits for the second consecutive year in FY25. Orders dated August 20 (Acko General, IRDAI/F&I/ORD/MISC/109/8/2026; Niva Bupa Health, /110/8/2026) and August 21 (Edelweiss Life, /111/8/2026; Pramerica Life, /112/8/2026) were published in a 48-hour burst. Acko had the largest excess at Rs 334.78 crore, more than half of its permitted Rs 650.37 crore. Niva Bupa's excess was Rs 248.37 crore. IRDAI's FY25 annual report records that 23 insurers, eight in life and 15 in non-life, exceeded limits and sought forbearance, but only these four were sanctioned in this tranche after the General Insurance and Life Insurance Councils' pleas for leniency were rejected.
The Rule Behind the Ban Is Section 40B, Not Just a Circular
EoM limits are statutory under Section 40B of the Insurance Act, 1938, and were consolidated into the IRDAI (Expenses of Management, including Commission) Regulations, 2024 notified in January 2024, which is the instrument cited in all four orders. The framework caps management expenses as a function of gross written premium and brings commission, branch costs, technology and acquisition spend inside one ceiling, with a graded toolkit under Regulation 22: formal warnings, operational restrictions including a six-month ban on new places of business, transfer of excess to the shareholder P&L, curbs on KMP variable pay, and, for persistent breach, restrictions on writing classes of business up to licence cancellation. In May 2026 the regulator had already withheld CEO variable pay at EoM-breaching insurers; the August orders are the next rung on that ladder - the franchise, not just the P&L, is priced. The pleas for forbearance recorded in the orders and in Mint's Aug 25 explainer illustrate the tension: Acko cited gross written premium of Rs 2,067 crore against a projection of Rs 2,750 crore in a year of weak industry growth and a change in premium recognition as a direct-to-customer digital insurer; Niva Bupa cited expansion, technology and a brand transition; Edelweiss Life said its ratio improved from 135% of permitted spend in FY22 to 112% in FY25; Pramerica Life pointed to an improving trajectory. IRDAI refused forbearance for all four, having already denied it previously to three of them - only Niva Bupa had been granted forbearance in FY24.
Why a Branch Ban Looks Light but Acts Heavy
A six-month ban on new places of business does not affect existing policies, renewals or claims handling, and none of the orders makes a finding about solvency or claims-paying ability. That is precisely why insurers' stock-exchange disclosures sought to reassure - Niva Bupa told the NSE on Aug 20 it was within EoM limits in FY26 and Q1 FY27, Edelweiss Life told Mint it is compliant in FY26 - and why Business Standard noted most affected insurers already have pan-India networks so the near-term business hit may be limited. The heavier effect is on the economics that caused the breach. EoM breaches are overwhelmingly distribution-cost breaches; a ban on new infrastructure forces the insurer to bring expenses inside the limit using the network it already has, rather than spending to a larger premium base that mechanically dilutes the ratio. For Niva Bupa and Acko, which had argued technology spend as distinct from commission, former IRDAI member Nilesh Sathe's point in Mint is material: the EoM regulations already allow 5% additional expense for technology. Excess beyond that is not treated as exempt. The regulator's sequencing - first variable pay, then branch freeze, with the FY25 report noting 23 insurers were over the line - signals more orders are likely for insurers that remain non-compliant.
What Policyholders and Distributors Should Do
If you hold a policy with one of these four insurers, no action on the policy is needed. Renewals continue, existing branches continue, digital channels continue, and the orders say nothing about claim operations. The sensible use of the order is as a filter, not an alarm. Ask the intermediary to show the insurer's current EoM disclosure for FY26 and Q1 FY27 and the board minutes noting the order - Regulation 22 orders require the board to take note - rather than trading on a headline. Watch whether the insurer's expense ratio returns inside limits in the next two quarterly disclosures and whether any further action follows; only a pattern of breach plus further sanction, not a single corrective ban, would be a reason to reconsider a renewal recommendation. For a distributor, the second-order effect flagged by Sarvada's Aug 21 compliance analysis matters: EoM pressure is one of the channels through which commission negotiation will be disciplined in 2026, so a renewal desk should explain the restriction in those terms rather than moving a client reflexively.
Sources: Mint Explainer (Aug 25, 2026); Business Standard (Aug 23, 2026); Financial Express (Aug 20, 2026); Moneycontrol (Aug 24, 2026); The Hindu (Aug 21, 2026); Sarvada/Pratibimb analysis (Aug 21, 2026) parsing IRDAI orders 109-112/8/2026; IRDAI EoM Regulations, 2024 (Jan 2024) and Section 40B, Insurance Act 1938